Alnylam Pharmaceuticals Inc ALNY
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-05-28 |
| Shares Out. | 133,510,000 |
| Website | alnylam.com/ ↗ |
| Phone | 13026587581 |
| Employees | 2,500 |
| Revenue | $1.29B |
| Gross Profit | $992.7M |
| Net Income | $164.5M |
| Free Cash Flow | $793.9M |
| Total Assets | $5.56B |
| Total Liabilities | $4.20B |
| Equity | $1.35B |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Alnylam Pharmaceuticals Inc is a publicly traded company under the ticker symbol ALNY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.